Johnson & Johnson’s Tremfya Shows Crohn’s Disease Benefits Through Three Years

Johnson & Johnson has announced three-year clinical data showing that Tremfya (guselkumab) maintained clinical and endoscopic remission in adults with moderately to severely active Crohn’s disease. The results come from the Phase 3 GALAXI 2 and GALAXI 3 studies and highlight the drug’s potential to provide long-term disease control.

The latest findings were reported at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting. The Week 144 results showed sustained benefits across two Tremfya maintenance dosing regimens.

Among patients receiving Tremfya 100 mg every eight weeks, 94% achieved clinical remission after three years. In the group receiving 200 mg every four weeks, the rate was 91%.

Both dosing groups also showed positive results for corticosteroid-free remission. Around 88% of patients in each group achieved clinical remission without corticosteroid use for 90 days, an important measure for people who need to manage Crohn’s disease over the long term.

The study also assessed endoscopic remission, which measures improvement in inflammation and visible damage in the digestive tract. At Week 144, endoscopic remission was achieved by 52% of patients receiving the 100 mg dose every eight weeks and 61% of those receiving the 200 mg dose every four weeks.

Johnson & Johnson reported that 74% of patients treated with Tremfya remained on treatment through three years. The safety findings were consistent with the drug’s established safety profile in Crohn’s disease.

David Rubin, director of the Inflammatory Bowel Disease Center at the University of Chicago, said maintaining clinical and endoscopic outcomes for three years is particularly meaningful for patients living with a chronic condition. He added that the findings contribute to evidence supporting sustained remission and long-term disease management with Tremfya.

Crohn’s disease is a chronic inflammatory bowel disease that can affect the digestive tract and cause symptoms such as abdominal pain, diarrhoea, weight loss and rectal bleeding. The condition can vary in severity, and patients may experience periods of active disease followed by remission. Although there is currently no cure, treatments aim to control inflammation, reduce symptoms and help prevent complications.

Tremfya is a monoclonal antibody developed by Johnson & Johnson. It blocks interleukin-23 (IL-23), a protein involved in inflammation, and also binds to CD64, a receptor found on certain immune cells that produce IL-23. The company says the medicine is designed to target inflammation at its source, although the clinical significance of its CD64 binding mechanism remains under investigation.

The GALAXI programme is evaluating Tremfya in people with moderately to severely active Crohn’s disease, including patients who have not responded adequately to, or cannot tolerate, existing treatments. The long-term extension studies are designed to assess clinical outcomes and safety over an extended period.

The three-year results add to the evidence supporting Tremfya as a treatment option for Crohn’s disease. Further follow-up from the ongoing programme is expected to provide additional information on the medicine’s long-term effectiveness and safety.